First-in-human dose-escalating study of ABSK043, a novel and oral small-molecule inhibitor of PD-L1, in patients with advanced solid tumors

被引：2

作者：

Cooper, A. ^{[1
]}

Andelkovic, V. ^{[2
]}

Wilkinson, K. ^{[1
]}

Ganju, V. ^{[3
]}

Lundy, J. ^{[3
]}

Hong, M. ^{[1
]}

Airey, S. ^{[2
]}

Meng, L. L. ^{[4
]}

Shen, B. ^{[5
]}

Li, H. ^{[6
]}

Yao, L. ^{[7
]}

Zhang, M. ^{[3
,8
]}

Coward, J. ^{[2
]}

机构：

[1] Liverpool Hosp, Dept Med Oncol, South Western Sydney Local Hlth Dist, Liverpool, NSW, Australia

[2] ICON Canc Ctr South Brisbane, Dept Gynaeoncol, Brisbane, Qld, Australia

[3] Peninsula & Southeast Oncol, Dept Oncol, Frankston, Vic, Australia

[4] Abbisko Therapeut Co Ltd, Med Clin, Shanghai, Peoples R China

[5] Abbisko Therapeut Co Ltd, Translat Med, Shanghai, Peoples R China

[6] Abbisko Therapeut Co Ltd, Biometr, Shanghai, Peoples R China

[7] Abbisko Therapeut Co Ltd, Clin Pharmacol, Shanghai, Peoples R China

[8] Abbisko Therapeut Co Ltd, Clin Dev, Shanghai, Peoples R China

来源：

关键词：

D O I：

10.1016/j.annonc.2023.09.1886

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

700P

引用

页码：S487 / S487

页数：1